Globus Medical, Inc. $GMED Shares Sold by Bridge City Capital LLC

Bridge City Capital LLC trimmed its holdings in Globus Medical, Inc. (NYSE:GMED) by 27.5% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 84,082 shares of the medical device company’s stock after selling 31,893 shares during the quarter. Globus Medical makes up 2.2% of Bridge City Capital LLC’s holdings, making the stock its 6th biggest holding. Bridge City Capital LLC’s holdings in Globus Medical were worth $7,341,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. William Blair Investment Management LLC raised its position in shares of Globus Medical by 17.2% in the third quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock valued at $161,454,000 after buying an additional 414,134 shares during the last quarter. ANTIPODES PARTNERS Ltd raised its position in shares of Globus Medical by 49,020.3% in the third quarter. ANTIPODES PARTNERS Ltd now owns 891,043 shares of the medical device company’s stock valued at $51,034,000 after buying an additional 889,229 shares during the last quarter. Annex Advisory Services LLC acquired a new stake in shares of Globus Medical in the fourth quarter valued at about $20,572,000. Kingdon Capital Management L.L.C. raised its position in shares of Globus Medical by 51.6% in the third quarter. Kingdon Capital Management L.L.C. now owns 257,650 shares of the medical device company’s stock valued at $14,756,000 after buying an additional 87,650 shares during the last quarter. Finally, Kennedy Capital Management LLC raised its position in shares of Globus Medical by 44.6% in the third quarter. Kennedy Capital Management LLC now owns 490,949 shares of the medical device company’s stock valued at $28,117,000 after buying an additional 151,500 shares during the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical Trading Down 0.1%

Globus Medical stock opened at $80.44 on Friday. Globus Medical, Inc. has a 12-month low of $51.79 and a 12-month high of $101.40. The stock has a market cap of $10.92 billion, a P/E ratio of 18.71, a PEG ratio of 1.66 and a beta of 0.95. The company has a 50-day moving average price of $85.77 and a 200 day moving average price of $88.10.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. During the same period last year, the business earned $0.68 earnings per share. Globus Medical’s revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, analysts forecast that Globus Medical, Inc. will post 4.74 EPS for the current year.

Wall Street Analysts Forecast Growth

GMED has been the subject of a number of recent research reports. Piper Sandler reiterated an “overweight” rating on shares of Globus Medical in a research report on Tuesday. Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Royal Bank Of Canada increased their target price on shares of Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, May 8th. Needham & Company LLC increased their target price on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Finally, Wells Fargo & Company cut their price objective on shares of Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $106.36.

Insider Transactions at Globus Medical

In related news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the sale, the director directly owned 510,175 shares in the company, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 18.38% of the company’s stock.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.